17 Dec 2015 08:41
Sinclair IS Pharma plc
("Sinclair" or the "Company")
Completes £132m strategic disposal of non-aesthetics business to Alliance Pharma plc
Creates a fast growth, high margin pure-play differentiated aesthetics company
· Delivering a product portfolio operating in fast growing markets underpinned by geographic expansion and new product introductions
· Highly differentiated aesthetics brands addressing unmet market need for effective, high quality, minimally-invasive treatments
· Simplified business structure with a strong balance sheet with pro forma net cash of £82m to support future growth
· The Company remains in an offer period
London, 17 December 2015 further to the announcement on 26 November 2015, Sinclair IS Pharma plc (SPH.L), ("Sinclair" or the "Company") the international specialty pharma company, is pleased to announce it has completed the strategic disposal of its non-aesthetics business to Alliance Pharma plc for a total upfront cash consideration of £132m as well as sales-related royalty payments relating to Flammacerium US.
The terms of the transaction announced on 26 November 2015 remain unchanged.
Sinclair is now a pure-play highly differentiated aesthetics company, operating in a high growth, self-pay market with high gross margin. Sinclair's balance sheet has now been transformed, leaving the Company with a pro-forma net cash position of £82m to invest in future growth opportunities and to cover milestone payments from historical acquisitions. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years.
As announced on 26 November 2015 the Company remains in an offer period under the framework provided by a formal sales process under the Takeover Code.
Tomorrow the Company will formally change its name to Sinclair Pharma plc, the TIDM will remain SPH.L.
For further information please contact:
Sinclair IS Pharma plc | Tel: +44 (0) 20 7467 6920 |
Chris Spooner | |
Alan Olby |
Rothschild | Tel: +44 (0) 20 7280 5000 |
Julian Hudson |
Peel Hunt LLP (NOMAD and Broker) | Tel: +44 (0) 20 7418 8900 |
James Steel Oliver Jackson |
Media enquiries
FTI Consulting | Tel: +44 (0) 203 727 1000 |
Ben Atwell Brett Pollard |
Notes to Editors:
About Sinclair IS Pharma plc - www.sinclairpharma.com
Sinclair IS Pharma plc is an international company that operates in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. The group has an established sales and marketing presence in the leading EU markets' and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.